GP73 inhibition alleviates hepatic fibrosis by suppressing TGF-β/mTOR signaling pathways
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2026-08 · 1872 (6) · 168263
DOI: 10.1016/j.bbadis.2026.168263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2026-08. Verfasst von Yue Guo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China; College of Basic Medical Science, Ch…. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Signal Transduction, Liver Cirrhosis, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatic fibrosis, a hallmark of chronic liver diseases, arises from persistent activation of hepatic stellate cells (HSCs). Golgi protein 73 (GP73) is a recognized fibrosis biomarker, yet its active role in driving fibrogenesis and the underlying molecular mechanisms remain poorly defined. Using wild-type, GP73 knockout, and knock-in mouse models, we demonstrate that GP73 expression is not merely a marker but a key functional modulator of fibrotic progression, correlates strongly with fibrosis severity. While these genetic models do not develop spontaneous hepatic fibrosis under basal conditions-notwithstanding the potential metabolic roles of GP73-our results demonstrate that GP73 expression levels significantly dictate the severity of CCl4-induced fibrotic progression. Mechanistically, endogenous co-immunoprecipitation (Co-IP) revealed that GP73 physically interacts with TGF-β receptor 1 (TGFBR1), mTOR, and the recycling endosome marker Rab11. GP73 enhances HSC activation by amplifying TGF-β and mTOR signaling through the inhibition of key fibrotic factors' degradation, such as TGFBR1 and mTOR. Protein half-life and rescue experiments confirmed that GP73 prevents the lysosomal degradation of TGFBR1 and mTOR; notably, re-introducing GP73 into knockdown cells successfully restored receptor stability and downstream signaling. Furthermore, pharmacological disruption of endocytic trafficking with Brefeldin A (BFA) abolished the protective effect of GP73, leading to accelerated receptor degradation. Suppressing GP73 reduced HSC activation and attenuated collagen deposition in vivo. Our findings identify GP73 as a molecular scaffold that reroutes fibrotic signaling complexes into the recycling pathway and away from degradation. Consequently, our results position GP73-mediated endocytic recycling as a potential therapeutic target and a viable adjunctive strategy for managing chronic liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China; College of Basic Medical Science, China Three Gorges University, Yichang, China; Institute of Organ Fibros…
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China; Institute of Organ Fibrosis and Targeted Drug Delivery, China Three Gorges University, Yichang, China; Col…
- Institute of Organ Fibrosis and Targeted Drug Delivery, The People's Hospital, China Three Gorges University, Yichang, China.
- State Key Laboratory of Medical Molecular Biology, Department of Physiology, Institute of Basic Medical Sciences, School of Basic Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, Chi…
- The Second College of Clinical Medical Science, China Three Gorges University, Yichang, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Guo, Y., Liu, M. Y., Mo, Y. Q., Wan, L. Y., Wang, Y. N., Wang, S. Y., Ni, Y. R., Li, Z. Y., Wang, Y., Wang, X. L., Ma, L., Zhang, R. T., Zhang, Y. Q., Liu, C. B., Zhang, H. B., Li, B. T., & Wu, J. F. (2026). GP73 inhibition alleviates hepatic fibrosis by suppressing TGF-β/mTOR signaling pathways. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1872(6), 168263. https://doi.org/10.1016/j.bbadis.2026.168263
Vancouver
Guo Y, Liu MY, Mo YQ, Wan LY, Wang YN, Wang SY, et al. GP73 inhibition alleviates hepatic fibrosis by suppressing TGF-β/mTOR signaling pathways. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2026;1872(6):168263. doi:10.1016/j.bbadis.2026.168263
BibTeX
@article{Guo2026,
author = {Guo, Yue and Liu, Meng-Yuan and Mo, Yun-Qi and Wan, Lin-Yan and Wang, Ya-Nan and Wang, Sheng-Yong and Ni, Yi-Ran and Li, Zhi-Ying and Wang, Ying and Wang, Xiao-Lian and Ma, Lan and Zhang, Rui-Tao and Zhang, Yan-Qiong and Liu, Chang-Bai and Zhang, Hong-Bing and Li, Bo-Tao and Wu, Jiang-Feng},
title = {GP73 inhibition alleviates hepatic fibrosis by suppressing TGF-β/mTOR signaling pathways},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2026},
volume = {1872},
number = {6},
pages = {168263},
doi = {10.1016/j.bbadis.2026.168263}
}
EUVIMED